A Randomized Phase III Trial INcorporating Pathologic Complete ReSponse in Participants with Early StaGe Non Small Cell Lung Cancer to Optimize ImmunotHerapy in the AdjuvanT Setting (INSIGHT)
Eligible for screening study DCP 001
Completion of Pre-Registration QOLs is required after consent, prior to registration. Please see study documents.
